Clinical Trial Update: Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients [Phase 4]

View source ↗

Summary

A Phase 4 study reports results on the effect of saxagliptin on endothelial progenitor cells as a biomarker of endothelial dysfunction in patients with early ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Saxagliptin (saxagliptin)

Snippet

Sponsor: George Washington University | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED | Results posted: 2019-01-29